These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18978494)

  • 1. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.
    Hunt T; Clarke K
    Clin Neuropharmacol; 2009; 32(1):28-31. PubMed ID: 18978494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics.
    Behrensdorf-Nicol HA; Wild E; Bonifas U; Klimek J; Hanschmann KM; Krämer B; Kegel B
    Toxicol In Vitro; 2018 Dec; 53():80-88. PubMed ID: 30016653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
    Wang L; Sun Y; Yang W; Lindo P; Singh BR
    Toxicon; 2014 May; 82():52-60. PubMed ID: 24560879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination.
    Pellett S; Tepp WH; Toth SI; Johnson EA
    J Pharmacol Toxicol Methods; 2010; 61(3):304-10. PubMed ID: 20100585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
    Kim SB; Ban B; Jung KS; Yang GH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the dissociation of botulinum neurotoxin type A complexes.
    Eisele KH; Fink K; Vey M; Taylor HV
    Toxicon; 2011 Mar; 57(4):555-65. PubMed ID: 21195107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.
    Kim SH; Kim SB; Yang GH; Rhee CH
    Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).
    Bigalke H; Rummel A
    Toxins (Basel); 2015 Nov; 7(12):4895-905. PubMed ID: 26610569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.
    Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J
    J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
    Wohlfarth K; Sycha T; Ranoux D; Naver H; Caird D
    Curr Med Res Opin; 2009 Jul; 25(7):1573-84. PubMed ID: 19463043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SNARE cleavage products generated by formulated botulinum neurotoxin type-a drug products.
    Hunt T; Rupp D; Shimizu G; Tam K; Weidler J; Xie J
    Toxins (Basel); 2010 Aug; 2(8):2198-212. PubMed ID: 22069680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.
    Kukreja R; Chang TW; Cai S; Lindo P; Riding S; Zhou Y; Ravichandran E; Singh BR
    Toxicon; 2009 May; 53(6):616-24. PubMed ID: 19673075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
    Wohlfarth K; Kampe K; Bigalke H
    Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.